cagrilintide plus semaglutide for obesity management Weight Loss Efficacy of and In the REDEFINE 2 phase
Description
Britton C, McCormick FM, Renfrew MJ, Wade A, King SE
reviewed thirty-five phase 3 randomized clinical trials with over 20,000 patients and did not find an increased incidence in all-cause mortality, major adverse cardiovascular events and venous thromboembolism in patients on these medications compared to patients in placebo or active comparator groups
When paired with semaglutide, weight loss can reach up to 17% of body weight during the same timeframe ( 1, 2 )
M.KhanS.BalochN.et al (2018)
00402-4/asset/7d856d37-1b1d-4481-9723-c6f28077488d/main.assets/gr2_lrg.jpg)
